Opportunity Information: Apply for PAR 23 270
This NIH funding opportunity (PAR 23-270) supports R01 research grants that run clinical trials to test new and practical ways to implement Screening, Brief Intervention, and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drug (ATOD) use and misuse among adults who experience health disparities. It is led by the NIH Office of Disease Prevention (ODP) in partnership with multiple NIH Institutes, Centers, and Offices, reflecting an emphasis on prevention-focused, real-world strategies that can be adopted and sustained in settings where underserved populations receive care or services. The central goal is not simply to study whether SBIRT works in theory, but to prospectively test innovative implementation approaches, meaning applicants are expected to evaluate how SBIRT/P can be delivered effectively, consistently, and at scale in routine practice, while addressing barriers that contribute to inequitable health outcomes.
SBIRT/P, as used in this announcement, refers to a structured set of actions: screening individuals to identify risk levels related to ATOD use and misuse, delivering a brief intervention that typically involves a focused conversation aimed at increasing awareness and motivating behavior change, and then providing referral either to treatment or to preventive services when needed. The addition of "or Prevention" highlights that referral pathways are not limited to specialty treatment; they can also include services meant to prevent escalation, reduce harm, or connect people to supportive resources earlier. Applications should therefore consider the full continuum of care, including how screening results trigger next steps, how brief interventions are delivered (by whom, when, and with what tools), and how referral processes are made actionable, timely, and acceptable to participants.
A key expectation is that studies will be carried out in collaboration with healthcare and community partners. This points to research designs that are embedded in real delivery systems such as primary care clinics, emergency departments, community health centers, behavioral health settings, public health programs, social service agencies, housing services, and other community-based organizations that routinely interact with populations experiencing disparities. Competitive projects will typically show strong partnerships and clear operational plans for integrating SBIRT/P into workflows, training staff, using health information technology where appropriate, and ensuring follow-through on referrals. Because this is a clinical trial required mechanism, the project must include prospective assignment to an intervention and measure health- or behavior-related outcomes, while also often capturing implementation outcomes like reach, adoption, fidelity, acceptability, feasibility, cost, and sustainability.
The opportunity is categorized as discretionary funding and uses the NIH grant mechanism under an R01. It falls under health and education activity categories and is associated with CFDA numbers 93.121, 93.273, 93.279, 93.307, 93.313, and 93.399, indicating participation across multiple NIH components. While the notice references that the specific research interests of participating NIH Institutes, Centers, and Offices are detailed in the full announcement, the overall theme is consistent: rigorous, forward-looking tests of SBIRT/P implementation strategies that can reduce disparities in substance-related harms and improve outcomes in adult populations that have historically had less access to effective prevention and treatment services.
Eligibility is broad and includes many types of U.S.-based organizations and government entities. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with and without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; public housing authorities; and Native American tribal governments (federally recognized) and other tribal organizations. The notice also calls out additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it clearly restricts non-U.S. entities: foreign institutions and other non-domestic organizations are not eligible to apply, and non-domestic components of U.S. organizations are not eligible. However, foreign components, as NIH defines them in its Grants Policy Statement, are allowed, meaning certain discrete, well-justified international elements may be permitted when they are part of a U.S.-led application and meet NIH policy requirements.
The opportunity was created on August 16, 2023, and lists an original closing date of May 7, 2027, indicating a multi-year window in which applications can be submitted for relevant receipt dates tied to the NOFO. The award ceiling and expected number of awards are not specified in the provided summary, which is common for NIH notices where budgets are shaped by the scope of the proposed project, NIH policy limits, and available appropriations. Overall, this NOFO is aimed at teams that can run a well-designed clinical trial while also dealing directly with the practical realities of delivering SBIRT/P in settings serving adults facing disproportionate substance-related risks and consequences, with the broader intention of generating evidence that can be translated into routine practice and help close equity gaps.Apply for PAR 23 270
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.273, 93.279, 93.307, 93.313, 93.399.
- This funding opportunity was created on 2023-08-16.
- Applicants must submit their applications by 2027-05-07.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-23-270 (R01) - Implementing SBIRT/P for ATOD Use and Misuse Among Adults Experiencing Health Disparities
1) What is PAR-23-270, in plain terms?
PAR-23-270 is an NIH funding opportunity that supports R01 research grants for clinical trials focused on testing practical, real-world ways to implement SBIRT/P for alcohol, tobacco, and other drug (ATOD) use and misuse among adults who experience health disparities.
2) What type of grant mechanism does this opportunity use?
This opportunity uses the NIH R01 research project grant mechanism.
3) Is a clinical trial required for this funding opportunity?
Yes. The description indicates this is a clinical trial required mechanism, meaning the project must include prospective assignment to an intervention and measure health- or behavior-related outcomes.
4) What is SBIRT/P in this announcement?
SBIRT/P refers to Screening, Brief Intervention, and Referral to Treatment or Prevention. It is described as a structured set of actions that includes:
- Screening individuals to identify risk levels related to ATOD use and misuse
- Delivering a brief intervention (typically a focused conversation to increase awareness and motivate behavior change)
- Providing referral to treatment or to preventive services when needed
5) What does the "or Prevention" part change compared to traditional SBIRT?
The "or Prevention" language clarifies that referrals are not limited to specialty treatment. Referral pathways can also include preventive or supportive services intended to prevent escalation, reduce harm, or connect people to resources earlier along the continuum of care.
6) What is the main goal of the research supported by this NOFO?
The central goal is to prospectively test innovative implementation approaches for SBIRT/P in routine practice. The emphasis is not just whether SBIRT works in theory, but how SBIRT/P can be delivered effectively, consistently, and at scale in real-world settings, while addressing barriers that contribute to inequitable health outcomes.
7) What kinds of outcomes are expected to be measured?
Projects must measure health- or behavior-related outcomes as part of the clinical trial. The opportunity also highlights implementation outcomes that are commonly important in embedded real-world studies, such as reach, adoption, fidelity, acceptability, feasibility, cost, and sustainability.
8) What does "innovative implementation approaches" mean in this context?
Based on the description, it means approaches that improve how SBIRT/P is integrated and delivered in routine practice. Examples of the kinds of practical areas applicants are expected to evaluate include workflows, staff training, use of health information technology (where appropriate), and making referral processes actionable, timely, and acceptable to participants.
9) Which populations are the focus of the SBIRT/P implementation research here?
The focus is on adults who experience health disparities, particularly adults who have historically had less access to effective prevention and treatment services for substance-related harms.
10) What kinds of settings are considered appropriate for conducting the studies?
The studies are expected to be carried out in collaboration with healthcare and community partners and embedded in real delivery systems. The announcement cites examples such as:
- Primary care clinics
- Emergency departments
- Community health centers
- Behavioral health settings
- Public health programs
- Social service agencies
- Housing services
- Other community-based organizations serving underserved populations
11) Is partnership with community or healthcare organizations required or just encouraged?
The opportunity describes collaboration with healthcare and community partners as a key expectation. Competitive projects are expected to demonstrate strong partnerships and clear operational plans for integrating SBIRT/P into real-world workflows.
12) What does the NOFO suggest about how SBIRT/P should be operationalized?
Applications should consider the full continuum of care, including how screening results trigger next steps, how brief interventions are delivered (by whom, when, and using what tools), and how referral processes are made actionable, timely, and acceptable to participants.
13) Who is leading this funding opportunity at NIH?
It is led by the NIH Office of Disease Prevention (ODP) in partnership with multiple NIH Institutes, Centers, and Offices.
14) What is the overall emphasis of NIH in this opportunity?
The emphasis is prevention-focused, real-world strategies that can be adopted and sustained in settings where underserved populations receive care or services, with the intent of reducing disparities in substance-related harms and improving outcomes.
15) What is the activity category for this opportunity?
The opportunity is associated with health and education activity categories.
16) Is this discretionary funding?
Yes. The opportunity is categorized as discretionary funding.
17) Which CFDA numbers are associated with this opportunity?
The summary associates this NOFO with CFDA numbers 93.121, 93.273, 93.279, 93.307, 93.313, and 93.399, reflecting participation across multiple NIH components.
18) What organizations are eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and government entities. Eligible applicants include:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations with or without 501(c)(3) status
- For-profit organizations (other than small businesses), as well as small businesses
- Public housing authorities
- Native American tribal governments (federally recognized) and other tribal organizations
- U.S. territories or possessions
- Faith-based or community-based organizations
- Regional organizations
- Eligible federal agencies
19) Are minority-serving institutions specifically mentioned as eligible?
Yes. The notice calls out additional eligible applicant types including HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
20) Are foreign organizations eligible to apply directly?
No. Foreign institutions and other non-domestic organizations are not eligible to apply.
21) Are non-domestic components of U.S. organizations eligible?
No. Non-domestic components of U.S. organizations are not eligible, according to the summary provided.
22) Are any international elements allowed at all?
Yes. The summary states that foreign components, as NIH defines them in its Grants Policy Statement, are allowed when they are part of a U.S.-led application and meet NIH policy requirements.
23) When was this funding opportunity created?
The opportunity was created on August 16, 2023.
24) What is the closing date listed in the summary?
The summary lists an original closing date of May 7, 2027, indicating a multi-year window for submitting applications on relevant receipt dates tied to the NOFO.
25) Does the summary specify an award ceiling or number of awards?
No. The award ceiling and expected number of awards are not specified in the provided summary.
26) What kinds of projects are likely to be competitive under this NOFO?
Based on the summary, competitive projects will typically include a well-designed clinical trial plus strong healthcare/community partnerships and a clear operational plan for integrating SBIRT/P into routine practice, including training, workflow integration, potential use of health information technology, and reliable referral follow-through.
27) What is the broader intended impact of this research?
The broader intent is to generate evidence that can be translated into routine practice to improve prevention and care delivery for ATOD-related risks and harms among adults experiencing disparities, helping close equity gaps.
Browse more opportunities from the same category: Education, Health
Next opportunity: Japanese American Confinement Sites Grant Program
Previous opportunity: Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 270
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 270) also looked into and applied for these:
| Funding Opportunity |
|---|
| Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) Apply for PAR 23 253 Funding Number: PAR 23 253 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) Apply for PAR 23 281 Funding Number: PAR 23 281 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) Apply for RFA CA 23 042 Funding Number: RFA CA 23 042 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional) Apply for RFA DA 25 018 Funding Number: RFA DA 25 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) Apply for PAR 23 279 Funding Number: PAR 23 279 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) Apply for PAR 23 280 Funding Number: PAR 23 280 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01) Apply for PAR 24 027 Funding Number: PAR 24 027 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial Required) Apply for RFA CA 24 007 Funding Number: RFA CA 24 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Biotypes of CNS Complications in People Living with HIV (P01 Clinical Trial Not Allowed) Apply for RFA MH 24 235 Funding Number: RFA MH 24 235 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Firearm Injury Prevention in Community Healthcare Settings (R01 Clinical Trial Optional) Apply for RFA NR 24 001 Funding Number: RFA NR 24 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) Apply for PAR 23 292 Funding Number: PAR 23 292 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01 Clinical Trial Not Allowed) Apply for RFA DA 25 003 Funding Number: RFA DA 25 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional) Apply for RFA AA 23 006 Funding Number: RFA AA 23 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01 Clinical Trial Optional) Apply for RFA AA 23 005 Funding Number: RFA AA 23 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| NIDA REI: Academic Research Enhancement Award (AREA) Training a Diverse Data Science Workforce for Addiction Research (R15 Clinical Trial Not Allowed) Apply for RFA DA 24 026 Funding Number: RFA DA 24 026 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| NIDA REI: Training a Diverse Data Science Workforce for Addiction Research (R25 Clinical Trial Not Allowed) Apply for RFA DA 24 025 Funding Number: RFA DA 24 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Single Source: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed) Apply for RFA DA 25 015 Funding Number: RFA DA 25 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) Apply for PAR 23 277 Funding Number: PAR 23 277 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 016 Funding Number: RFA DA 25 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 017 Funding Number: RFA DA 25 017 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 270", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.